7171 Chemoradiotherapy with cisplatin (C) and gemcitabine (G) plus concurrent irradiation (XRT), for the conservative treatment of invasive transitional bladder cancer (ITBC) patients – clinical outcome and long term follow-up in a monoinstitutional experience

To evaluate paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) in patients with poor-prognosis nonseminomatous germ cell tumor (NSGCT). Paclitaxel is an active treatment of nonseminomatous germ cell tumors.The present study was an open-label, single-center, Phase II study. Chemotherapy-naive patients received T-BEP (paclitaxel 175 mg/m2 [day 2], cisplatin 20 mg/m2 [days 1-5], etoposide 100 mg/m2 [days 1-5], bleomycin 30 IU [days 1, 3, and...